A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called "bad" cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard ...
Nov 15, 2020
0
78